Angiotensin II type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-α2-deficient congenital muscular dystrophy (MDC1A)

Skeletal Muscle

Volumn 2, Issue 1, 2012, Pages

  Meinen, Sarina ^a   Lin, Shuo ^a   Ruegg, Markus A ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Angiotensin II; Fibrosis; losartan; Muscle regeneration; Notexin; Skeletal muscle; Smad2 3; TGF

Indexed keywords

EID: 84874716506     PISSN: None     EISSN: 20445040     Source Type: Journal    
DOI: 10.1186/2044-5040-2-18     Document Type: Article

References (53)

1. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, AP-Rhys CM, Holm TM, Loeys BL, et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007, 13:204-210. 10.1038/nm1536, 3138130, 17237794.
2. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390:465-471. 10.1038/37284, 9393997.
3. Li Y, Foster W, Deasy BM, Chan Y, Prisk V, Tang Y, Cummins J, Huard J. Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. Am J Pathol 2004, 164:1007-1019. 10.1016/S0002-9440(10)63188-4, 1614716, 14982854.
4. Allen RE, Boxhorn LK. Inhibition of skeletal muscle satellite cell differentiation by transforming growth factor-beta. J Cell Physiol 1987, 133:567-572. 10.1002/jcp.1041330319, 3480289.
5. Rahimi RA, Leof EB. TGF-beta signaling: a tale of two responses. J Cell Biochem 2007, 102:593-608. 10.1002/jcb.21501, 17729308.
6. Burks TN, Cohn RD. Role of TGF-beta signaling in inherited and acquired myopathies. Skelet Muscle 2011, 1:19. 10.1186/2044-5040-1-19, 3156642, 21798096.
7. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell research 2009, 19:128-139. 10.1038/cr.2008.328, 2635127, 19114990.
8. Gosselin LE, Williams JE, Deering M, Brazeau D, Koury S, Martinez DA. Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle. Muscle Nerve 2004, 30:645-653. 10.1002/mus.20150, 15389721.
9. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003, 33:407-411. 10.1038/ng1116, 12598898.
10. Yamazaki M, Minota S, Sakurai H, Miyazono K, Yamada A, Kanazawa I, Kawai M. Expression of transforming growth factor-beta 1 and its relation to endomysial fibrosis in progressive muscular dystrophy. Am J Pathol 1994, 144:221-226. 1887141, 8311110.
11. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, Puffenberger EG, Hamosh A, Nanthakumar EJ, Curristin SM, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991, 352:337-339. 10.1038/352337a0, 1852208.
12. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006, 312:117-121. 10.1126/science.1124287, 1482474, 16601194.
13. Burks TN, Andres-Mateos E, Marx R, Mejias R, Van Erp C, Simmers JL, Walston JD, Ward CW, Cohn RD. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci Transl Med 2011, 3:82. ra37.
14. Bish LT, Yarchoan M, Sleeper MM, Gazzara JA, Morine KJ, Acosta P, Barton ER, Sweeney HL. Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice. PLoS One 2011, 6:e20856. 10.1371/journal.pone.0020856, 3120761, 21731628.
15. Spurney CF, Sali A, Guerron AD, Iantorno M, Yu Q, Gordish-Dressman H, Rayavarapu S, van der Meulen J, Hoffman EP, Nagaraju K. Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J Cardiovasc Pharmacol Ther 2011, 16:87-95. 10.1177/1074248410381757, 21304057.
16. Muntoni F, Brockington M, Brown SC. Glycosylation eases muscular dystrophy. Nat Med 2004, 10:676-677. 10.1038/nm0704-676, 15229511.
17. Patton BL, Miner JH, Chiu AY, Sanes JR. Distribution and function of laminins in the neuromuscular system of developing, adult, and mutant mice. J Cell Biol 1997, 139:1507-1521. 10.1083/jcb.139.6.1507, 2132624, 9396756.
18. Kuang W, Xu H, Vilquin JT, Engvall E. Activation of the lama2 gene in muscle regeneration: abortive regeneration in laminin alpha2-deficiency. Lab Invest 1999, 79:1601-1613.
19. Meinen S, Barzaghi P, Lin S, Lochmuller H, Ruegg MA. Linker molecules between laminins and dystroglycan ameliorate laminin-alpha2-deficient muscular dystrophy at all disease stages. J Cell Biol 2007, 176:979-993. 10.1083/jcb.200611152, 2064083, 17389231.
20. Miyagoe Y, Hanaoka K, Nonaka I, Hayasaka M, Nabeshima Y, Arahata K, Takeda S. Laminin alpha2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy. FEBS Lett 1997, 415:33-39. 10.1016/S0014-5793(97)01007-7, 9326364.
21. Bentzinger CF, Barzaghi P, Lin S, Ruegg MA. Overexpression of mini-agrin in skeletal muscle increases muscle integrity and regenerative capacity in laminin-alpha2-deficient mice. FASEB J 2005, 19:934-942. 10.1096/fj.04-3376com, 15923403.
22. Helbling-Leclerc A, Zhang X, Topaloglu H, Cruaud C, Tesson F, Weissenbach J, Tome FM, Schwartz K, Fardeau M, Tryggvason K, et al. Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat Genet 1995, 11:216-218. 10.1038/ng1095-216, 7550355.
23. Kuang W, Xu H, Vachon PH, Engvall E. Disruption of the lama2 gene in embryonic stem cells: laminin alpha 2 is necessary for sustenance of mature muscle cells. Exp Cell Res 1998, 241:117-125. 10.1006/excr.1998.4025, 9633519.
24. Kuang W, Xu H, Vachon PH, Liu L, Loechel F, Wewer UM, Engvall E. Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models. J Clin Invest 1998, 102:844-852. 10.1172/JCI3705, 508948, 9710454.
25. Moll J, Barzaghi P, Lin S, Bezakova G, Lochmuller H, Engvall E, Muller U, Ruegg MA. An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature 2001, 413:302-307. 10.1038/35095054, 11565031.
26. Gawlik K, Miyagoe-Suzuki Y, Ekblom P, Takeda S, Durbeej M. Laminin alpha1 chain reduces muscular dystrophy in laminin alpha2 chain deficient mice. Hum Mol Genet 2004, 13:1775-1784. 10.1093/hmg/ddh190, 15213105.
27. Gawlik KI, Durbeej M. Transgenic overexpression of laminin alpha1 chain in laminin alpha2 chain-deficient mice rescues the disease throughout the lifespan. Muscle Nerve 2010, 42:30-37. 10.1002/mus.21616, 20544910.
28. Qiao C, Li J, Zhu T, Draviam R, Watkins S, Ye X, Chen C, Xiao X. Amelioration of laminin-alpha2-deficient congenital muscular dystrophy by somatic gene transfer of miniagrin. Proc Natl Acad Sci U S A 2005, 102:11999-12004. 10.1073/pnas.0502137102, 1189311, 16103356.
29. Dominov JA, Kravetz AJ, Ardelt M, Kostek CA, Beermann ML, Miller JB. Muscle-specific BCL2 expression ameliorates muscle disease in laminin {alpha}2-deficient, but not in dystrophin-deficient, mice. Hum Mol Genet 2005, 14:1029-1040. 10.1093/hmg/ddi095, 15757977.
30. Erb M, Meinen S, Barzaghi P, Sumanovski LT, Courdier-Fruh I, Ruegg MA, Meier T. Omigapil ameliorates the pathology of muscle dystrophy caused by laminin-alpha2 deficiency. J Pharmacol Exp Ther 2009, 331:787-795. 10.1124/jpet.109.160754, 19759319.
31. Girgenrath M, Beermann ML, Vishnudas VK, Homma S, Miller JB. Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy. Ann Neurol 2009, 65:47-56. 2639627, 19086074.
32. Girgenrath M, Dominov JA, Kostek CA, Miller JB. Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy. J Clin Invest 2004, 114:1635-1639. 529286, 15578095.
33. Carmignac V, Quere R, Durbeej M. Proteasome inhibition improves the muscle of laminin alpha2 chain-deficient mice. Hum Mol Genet 2011, 20:541-552. 10.1093/hmg/ddq499, 21084425.
34. Carmignac V, Svensson M, Korner Z, Elowsson L, Matsumura C, Gawlik KI, Allamand V, Durbeej M. Autophagy is increased in laminin alpha2 chain-deficient muscle and its inhibition improves muscle morphology in a mouse model of MDC1A. Hum Mol Genet 2011, 20:4891-4902. 10.1093/hmg/ddr427, 21920942.
35. Guo LT, Zhang XU, Kuang W, Xu H, Liu LA, Vilquin JT, Miyagoe-Suzuki Y, Takeda S, Ruegg MA, Wewer UM, Engvall E. Laminin alpha2 deficiency and muscular dystrophy; genotype-phenotype correlation in mutant mice. Neuromuscul Disord 2003, 13:207-215. 10.1016/s0960-8966(02)00266-3, 12609502.
36. Nevo Y, Halevy O, Genin O, Moshe I, Turgeman T, Harel M, Biton E, Reif S, Pines M. Fibrosis inhibition and muscle histopathology improvement in laminin-alpha2-deficient mice. Muscle Nerve 2010, 42:218-229. 10.1002/mus.21706, 20589893.
37. Elbaz M, Yanay N, Aga-Mizrachi S, Brunschwig Z, Kassis I, Ettinger K, Barak V, Nevo Y. Losartan, a therapeutic candidate in congenital muscular dystrophy: Studies in the dy(2 J) /dy(2 J) Mouse. Ann Neurol 2012, 71:699-708. 10.1002/ana.22694, 22522482.
38. Bernasconi P, Di Blasi C, Mora M, Morandi L, Galbiati S, Confalonieri P, Cornelio F, Mantegazza R. Transforming growth factor-beta1 and fibrosis in congenital muscular dystrophies. Neuromuscul Disord 1999, 9:28-33. 10.1016/S0960-8966(98)00093-5, 10063832.
39. Siegl PK, Chang RS, Mantlo NB, Chakravarty PK, Ondeyka DL, Greenlee WJ, Patchett AA, Sweet CS, Lotti VJ. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist. J Pharmacol Exp Ther 1992, 262:139-144.
40. Luna L. Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology In Volume 3rd Ed 1968, 94-95. New York: McGraw-Hill.
41. Miyagoe-Suzuki Y, Nakagawa M, Takeda S. Merosin and congenital muscular dystrophy. Microsc Res Tech 2000, 48:181-191. 10.1002/(SICI)1097-0029(20000201/15)48:3/4<181::AID-JEMT6>3.0.CO;2-Q, 10679965.
42. Briguet A, Courdier-Fruh I, Foster M, Meier T, Magyar JP. Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. Neuromuscul Disord 2004, 14:675-682. 10.1016/j.nmd.2004.06.008, 15351425.
43. Cohen SA, Bidlingmeyer BA, Tarvin TL. PITC derivatives in amino acid analysis. Nature 1986, 320:769-770. 10.1038/320769a0, 3703004.
44. Naito T, Masaki T, Nikolic-Paterson DJ, Tanji C, Yorioka N, Kohno N. Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1. Am J Physiol Renal Physiol 2004, 286:F278-287. 10.1152/ajprenal.00139.2003, 14583433.
45. Zhou Y, Poczatek MH, Berecek KH, Murphy-Ullrich JE. Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions. Biochem Biophys Res Commun 2006, 339:633-641. 10.1016/j.bbrc.2005.11.060, 16310163.
46. Ishitobi M, Haginoya K, Zhao Y, Ohnuma A, Minato J, Yanagisawa T, Tanabu M, Kikuchi M, Iinuma K. Elevated plasma levels of transforming growth factor beta1 in patients with muscular dystrophy. Neuroreport 2000, 11:4033-4035. 10.1097/00001756-200012180-00026, 11192624.
47. Meinen S, Lin S, Thurnherr R, Erb M, Meier T, Ruegg MA. Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy mice. EMBO Mol Med 2011, 3:465-479. 10.1002/emmm.201100151, 3377088, 21674808.
48. Carlson ME, Hsu M, Conboy IM. Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells. Nature 2008, 454:528-532. 10.1038/nature07034, 18552838.
49. Kumar A, Yamauchi J, Girgenrath T, Girgenrath M. Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1A. Hum Mol Genet 2011, 20:2333-2343. 10.1093/hmg/ddr126, 3098729, 21441569.
50. Rooney JE, Knapp JR, Hodges BL, Wuebbles RD, Burkin DJ. Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-deficient congenital muscular dystrophy. Am J Pathol 2012, 180:1593-1602. 10.1016/j.ajpath.2011.12.019, 22322301.
51. Ruegg MA, Glass DJ. Molecular mechanisms and treatment options for muscle wasting diseases. Annu Rev Pharmacol Toxicol 2011, 51:373-395. 10.1146/annurev-pharmtox-010510-100537, 20936944.
52. Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, Moore D, Pohlmann H, Sauer D, Silani V, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology 2007, 69:776-784. 10.1212/01.wnl.0000269676.07319.09, 17709710.
53. Olanow CW, Schapira AH, LeWitt PA, Kieburtz K, Sauer D, Olivieri G, Pohlmann H, Hubble J. TCH346 as a neuroprotective drug in Parkinson"s disease: a double-blind, randomised, controlled trial. Lancet Neurol 2006, 5:1013-1020. 10.1016/S1474-4422(06)70602-0, 17110281.